Navigation Links
Encouraging Phase III Study Results Show PET Imaging with Florbetaben Reliably Detects Beta-Amyloid in the Brain
Date:4/15/2012

serious medical conditions for improved patient outcomes."  Dr. Piramal also serves on the Dean's Advisory Board of both the Harvard School of Public Health and Harvard Business School.

This pivotal trial is the first to overlay MRI and PET data to accurately match florbetaben gray matter uptake with disease in six defined regions of the brain.  This was done to confirm that florbetaben binds to beta-Amyloid on both a regional (brain sections) and subject (whole brain) level. This combination provides considerably more data points than any other beta-Amyloid tracer trial to date. Based on a region-by-region comparison, florbetaben detected beta-Amyloid with a sensitivity of 77% and a specificity of 94% with substantial inter-reader agreement (kappa = 0.66), significantly exceeding the pre-specified threshold, confirming the study hypotheses.

Note to the Editors:

About Florbetaben (BAY 94-9172)

Florbetaben is an 18F-labeled PET tracer that specifically binds to deposition of beta-Amyloid. These depositions (plaques) consist of proteins that accumulate in the brain and are a pathological hallmark of Alzheimer's disease. As the aggregation of the beta-Amyloid protein in the brain is also a key target for new therapeutic treatments under development, florbetaben might also be able to support the development of these new treatment approaches. A Phase II study showed that patients with clinical diagnosis of Alzheimer's disease could be differentiated from age-matched healthy volunteers on the basis of florbetaben uptake pattern in the brain. The results of the Phase II study were presented at the International Conference on Alzheimer's diseases (ICAD) in Vienna, Austria in July 2009 and published in the Lancet Neurology in April 2011.

About Alzheimer's Disease

Alzheimer's disease is a devastating neuro-degenerative disease and the most common cause of dementia. Most cases of Alzheimer's disea
'/>"/>

SOURCE Piramal Healthcare Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Announces Encouraging Top-Line Results From Hepatobiliary Cohort in Phase II Trial of Chemosaturation System
2. SAR 1118 Demonstrates Encouraging Results in Phase 2 Study of Dry Eye Disease
3. Stimatix GI Reports Encouraging Interim Results
4. AFFiRiS AG - Encouraging Results From Phase I Studies of two Alzheimers Candidate Vaccines Trigger a EUR 10 Million Milestone Payment
5. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
6. Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer
7. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
8. Encouraging Gene Therapy Results in Genetic Form of Blindness
9. Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO
10. Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
11. PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014  Restore Health, a leading personalized ... announced that it is now offering pharmacogenetics testing ... individual based upon their particular genetic makeup. Comprehensive ... interaction between a patient,s genetics and their entire ... to provide this new service to healthcare providers ...
(Date:7/24/2014)... 24, 2014  Mettler-Toledo International Inc. (NYSE: ... Provided below are the highlights: , Sales ... compared with the prior year. Reported sales increased 5% ... Net earnings per diluted share as reported (EPS) were ... 2013. Adjusted EPS was $2.57, an increase of 9% ...
(Date:7/24/2014)... 2014  IGI Laboratories, Inc. (NYSE MKT: IG), a New ... its financial results for the second quarter ended June 30, ... Total revenues of $6.5 million in the second quarter of ... 2013 , Total revenues of $13.3 million for the ... over the same period in 2013 , Total revenues ...
Breaking Medicine Technology:Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... (Nasdaq: BIOD ) today reported financial results for the ... Year 2011 Financial Results Biodel reported a net loss ... or $0.20 per share, compared to a net loss of $11.1 ... prior year. Research and development expenses were $5.5 ...
... CFN ), a leading, global medical technology company, ... Dec. 31, 2010. "Our strong second quarter results ... Infection Prevention businesses, and a benefit from a lower tax ... had announced in November 2010 his plans to retire. On ...
Cached Medicine Technology:Biodel Reports First Quarter Fiscal Year 2011 Financial Results 2Biodel Reports First Quarter Fiscal Year 2011 Financial Results 3Biodel Reports First Quarter Fiscal Year 2011 Financial Results 4Biodel Reports First Quarter Fiscal Year 2011 Financial Results 5Biodel Reports First Quarter Fiscal Year 2011 Financial Results 6CareFusion Reports Second Quarter Fiscal 2011 Results 2CareFusion Reports Second Quarter Fiscal 2011 Results 3CareFusion Reports Second Quarter Fiscal 2011 Results 4CareFusion Reports Second Quarter Fiscal 2011 Results 5CareFusion Reports Second Quarter Fiscal 2011 Results 6CareFusion Reports Second Quarter Fiscal 2011 Results 7CareFusion Reports Second Quarter Fiscal 2011 Results 8CareFusion Reports Second Quarter Fiscal 2011 Results 9CareFusion Reports Second Quarter Fiscal 2011 Results 10CareFusion Reports Second Quarter Fiscal 2011 Results 11CareFusion Reports Second Quarter Fiscal 2011 Results 12CareFusion Reports Second Quarter Fiscal 2011 Results 13CareFusion Reports Second Quarter Fiscal 2011 Results 14CareFusion Reports Second Quarter Fiscal 2011 Results 15
(Date:7/25/2014)... (PRWEB) July 25, 2014 “You have a ... than 500 people and their loved ones across the U.S. ... a brain tumor diagnosis is typically met with confusion and ... new and difficult vocabulary, and make critical decisions about a ... tumor diagnosis is accompanied by a sense of isolation and ...
(Date:7/25/2014)... The North America Artificial lift market report defines ... analysis and forecast of revenue. The artificial lift market in ... in 2013 to around $7 billion by 2018, at a ... through the TOC of North America artificial lift market report, ... provides a glimpse of the segmentation in North America Artificial ...
(Date:7/25/2014)... Providence, RI (PRWEB) July 25, 2014 ... Island Quality Improvement Organization (QIO) was recently awarded ... from the Centers for Medicare & Medicaid Services ... to fourteen organizations across the United States, represent ... In order to successfully execute the contract initiatives, ...
(Date:7/25/2014)... Health Advocate™, Inc., the nation’s leading healthcare ... Corporation, is introducing its newest solution in an upcoming ... Quality. , The webinar will be held twice on ... at 2 PM ET. For more information or to ... or call 866.799.2655. , In an environment of escalating ...
(Date:7/25/2014)... July 25, 2014 -- The Elizabeth Glaser Pediatric ... between the Medicines Patent Pool (MPP) and Gilead ... fumarate (TAF), a promising new HIV medication. The ... Conference (AIDS 2014) in Melbourne, Australia. , ... trials, early data suggests it could be a ...
Breaking Medicine News(10 mins):Health News:American Brain Tumor Association to Expand Service Reach with Launch of Nationwide Volunteer Network 2Health News:American Brain Tumor Association to Expand Service Reach with Launch of Nationwide Volunteer Network 3Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Healthcentric Advisors and Qualidigm Partner to Improve the Healthcare Quality for New England 2Health News:Healthcentric Advisors and Qualidigm Partner to Improve the Healthcare Quality for New England 3Health News:Healthcentric Advisors and Qualidigm Partner to Improve the Healthcare Quality for New England 4Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 2Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 3
... updated the NCCN Guidelines for Venous Thromboembolic Disease, which ... (PE), and is a common condition in people with ... graduated compression stockings in prophylaxis and treatment, and a ... May 20 The National Comprehensive Cancer Network (NCCN) ...
... Alliance designed to benefit Californians with medical ... Medical Association (CMA), representing 35,000 physicians in ... the MedicAlert Foundation, the leading nonprofit providing ... teamed up to provide patients living with ...
... counseling also proved cost-effective, study finds , , WEDNESDAY, ... program that promoted exercise, healthy eating and quitting ... to moderate chronic obstructive pulmonary disease (COPD) and ... patients in the study were randomly assigned to ...
... Market is Reflected in Burgeoning Pipeline of More than ... from Decision ResourcesWALTHAM, Mass., May 20 Decision Resources, ... for pharmaceutical and healthcare issues, finds that the launch ... over the next 10 years will drive the type ...
... partnership with Axway to provide innovative solutions ... technologists to address the challenges of implementing ... cost-effective manner.BELLEVUE, Wash., May 20 Edifecs, ... simplification and systems interoperability, and Axway, a ...
... Directors of BD (Becton, Dickinson and Company) (NYSE: ... per common share, payable on June 30, 2009 to holders ... rate is $1.32 per share. About BD BD is ... sells medical devices, instrument systems and reagents. The Company is ...
Cached Medicine News:Health News:NCCN Updates Supportive Care Guidelines for VTE 2Health News:NCCN Updates Supportive Care Guidelines for VTE 3Health News:California Medical Association Joins MedicAlert Foundation to Offer Medical Identification for Members and Patients 2Health News:Healthier Lifestyle Can Cut COPD Symptoms 2Health News:The Launch and Uptake of More Than 20 Novel Drugs Over The Next 10 Years Will Drive $12.5 Billion Growth in the Type 2 Diabetes Market 2Health News:Edifecs(TM) and Axway Announce a Partnership Targeting Innovative HIPAA 5010 Migration Solutions. 2Health News:Edifecs(TM) and Axway Announce a Partnership Targeting Innovative HIPAA 5010 Migration Solutions. 3Health News:Edifecs(TM) and Axway Announce a Partnership Targeting Innovative HIPAA 5010 Migration Solutions. 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: